MediWound (NASDAQ:MDWD) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MediWound (NASDAQ:MDWD) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $25.00 price objective on the biopharmaceutical company’s stock.

MediWound Trading Up 4.4 %

Shares of MediWound stock opened at $16.72 on Friday. The stock has a market capitalization of $180.34 million, a price-to-earnings ratio of -5.77 and a beta of 0.80. MediWound has a 1-year low of $11.04 and a 1-year high of $24.00. The firm’s 50-day moving average price is $17.24 and its two-hundred day moving average price is $17.62.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the company posted ($0.24) earnings per share. As a group, equities research analysts predict that MediWound will post -2.6 EPS for the current year.

Hedge Funds Weigh In On MediWound

A number of institutional investors have recently modified their holdings of MDWD. MetLife Investment Management LLC acquired a new stake in shares of MediWound in the third quarter valued at approximately $89,000. Rhumbline Advisers acquired a new stake in shares of MediWound in the 2nd quarter valued at $131,000. Barclays PLC raised its position in shares of MediWound by 311.3% during the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 8,449 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of MediWound during the third quarter valued at $212,000. Finally, Bank of New York Mellon Corp bought a new position in MediWound in the second quarter valued at about $342,000. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.